Coordinated Financial Services Inc. Purchases Shares of 275 Eli Lilly and Company (NYSE:LLY)

Coordinated Financial Services Inc. purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm purchased 275 shares of the company’s stock, valued at approximately $212,000.

Several other hedge funds also recently modified their holdings of LLY. United Community Bank lifted its position in Eli Lilly and Company by 11.1% in the fourth quarter. United Community Bank now owns 1,197 shares of the company’s stock worth $924,000 after purchasing an additional 120 shares during the period. Personal CFO Solutions LLC lifted its position in Eli Lilly and Company by 20.5% in the fourth quarter. Personal CFO Solutions LLC now owns 3,302 shares of the company’s stock worth $2,549,000 after purchasing an additional 562 shares during the period. Barings LLC lifted its position in Eli Lilly and Company by 251.4% in the fourth quarter. Barings LLC now owns 1,669 shares of the company’s stock worth $1,288,000 after purchasing an additional 1,194 shares during the period. Dorsey & Whitney Trust CO LLC lifted its position in Eli Lilly and Company by 18.0% in the fourth quarter. Dorsey & Whitney Trust CO LLC now owns 49,602 shares of the company’s stock worth $38,293,000 after purchasing an additional 7,562 shares during the period. Finally, Naviter Wealth LLC lifted its position in Eli Lilly and Company by 82.4% in the fourth quarter. Naviter Wealth LLC now owns 10,019 shares of the company’s stock worth $7,734,000 after purchasing an additional 4,525 shares during the period. 82.53% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

LLY has been the subject of a number of analyst reports. StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Bank of America restated a “buy” rating and issued a $997.00 target price on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Wolfe Research started coverage on Eli Lilly and Company in a report on Friday, November 15th. They issued an “outperform” rating and a $1,000.00 price target for the company. Finally, Leerink Partners set a $950.00 price target on Eli Lilly and Company in a report on Friday, January 17th. Three equities research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. According to MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average price target of $1,007.50.

Eli Lilly and Company Price Performance

Shares of LLY opened at $868.59 on Monday. Eli Lilly and Company has a 52-week low of $711.40 and a 52-week high of $972.53. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The stock has a 50 day simple moving average of $826.63 and a 200 day simple moving average of $847.24. The firm has a market capitalization of $823.57 billion, a PE ratio of 74.17, a P/E/G ratio of 1.40 and a beta of 0.34.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Eli Lilly and Company announced that its Board of Directors has initiated a share repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s leadership believes its stock is undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.